12:00 AM
 | 
Dec 08, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Anagrelide CR: Completed Phase II enrollment

Galena completed enrollment of 18 patients with elevated platelet counts secondary to essential thrombocythemia and other myeloproliferative neoplasms in an open-label, U.S. Phase II trial of oral GALE-401...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >